Research progress of anti-fibrotic drugs that inhibit epithelial-mesenchymal transition in pulmonary fibrosis.
10.3760/cma.j.cn121094-20210628-00308
- VernacularTitle:抑制肺上皮间质转化的抗纤维化药物研究进展
- Author:
Li Bing ZHANG
1
;
Na ZHAO
2
;
Qi Ying NONG
2
Author Information
1. Department of Occupational Medical Laboratory of Guangdong Province Hospital For Occupational Disease Prevention And Treatment, Guangzhou 510300, China Acute Infectious Disease Control Department of Zengcheng Dstrict Center For Disease Control And Prevention, Guangzhou, 511399, China.
2. Department of Occupational Medical Laboratory of Guangdong Province Hospital For Occupational Disease Prevention And Treatment, Guangzhou 510300, China.
- Publication Type:Journal Article
- Keywords:
Epithelial-mesenchymal transition;
Pulmonary fibrosis;
Transforming growth factor
- MeSH:
Humans;
Epithelial-Mesenchymal Transition/drug effects*;
Fibrosis/drug therapy*;
Pulmonary Fibrosis/pathology*;
Signal Transduction;
Transforming Growth Factor beta1/metabolism*;
Antifibrotic Agents/therapeutic use*
- From:
Chinese Journal of Industrial Hygiene and Occupational Diseases
2023;41(1):72-77
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis is the end-stage pathological change of lung diseases, which seriously affects the respiratory function of human body. A large number of studies at home and abroad have confirmed that epithelial-mesenchymal transition (EMT) is an important intermediate stage in the development of pulmonary fibrosis. Inhibition of multiple pathways upstream and downstream of EMT, such as the classical Smads pathway and non-Smads pathway of TGF-1 can effectively inhibit the process of EMT and alleviate pulmonary fibrosis. This article will review the main conclusions of the mechanism of action of EMT as a target to improve the pathology of pulmonary fibrosis so far, and provide a theoretical basis and research direction for further research and development of anti-pulmonary fibrosis drugs.
